Outlook Therapeutics, Inc. (OTLK)
NASDAQ: OTLK · Real-Time Price · USD
6.06
+0.01 (0.17%)
Nov 4, 2024, 4:00 PM EST - Market closed
Outlook Therapeutics Stock Forecast
Stock Price Forecast
The 7 analysts with 12-month price forecasts for OTLK stock have an average target of 48.2, with a low estimate of 30 and a high estimate of 100. The average target predicts an increase of 695.38% from the current stock price of 6.06.
Analyst Consensus: Strong Buy
Analyst Ratings
The average analyst rating for OTLK stock from 7 stock analysts is "Strong Buy". This means that analysts believe this stock is likely to perform very well in the near future and significantly outperform the market.
Recommendation Trends
| Rating | Jun '24 | Jul '24 | Aug '24 | Sep '24 | Oct '24 | Nov '24 |
|---|---|---|---|---|---|---|
| Strong Buy | 6 | 6 | 6 | 6 | 6 | 6 |
| Buy | 1 | 1 | 1 | 1 | 1 | 1 |
| Hold | 2 | 2 | 2 | 0 | 0 | 0 |
| Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Strong Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Total | 9 | 9 | 9 | 7 | 7 | 7 |
Latest Forecasts
| Analyst | Firm | Rating | Rating | Action | Price Target | Upside | Date |
|---|---|---|---|---|---|---|---|
| BTIG | BTIG | Strong Buy Reiterates $50 | Strong Buy | Reiterates | $50 | +725.08% | Oct 18, 2024 |
| Ascendiant Capital | Ascendiant Capital | Strong Buy Maintains $35 → $33 | Strong Buy | Maintains | $35 → $33 | +444.55% | Sep 3, 2024 |
| Chardan Capital | Chardan Capital | Strong Buy Maintains $53 | Strong Buy | Maintains | $53 | +774.59% | Aug 16, 2024 |
| HC Wainwright & Co. | HC Wainwright & Co. | Strong Buy Reiterates $30 | Strong Buy | Reiterates | $30 | +395.05% | Aug 15, 2024 |
| HC Wainwright & Co. | HC Wainwright & Co. | Strong Buy Reiterates $30 | Strong Buy | Reiterates | $30 | +395.05% | May 17, 2024 |
Financial Forecast
Revenue This Year
n/a
Revenue Next Year
8.02M
EPS This Year
-5.21
from -4.72
EPS Next Year
-2.62
from -5.21
Revenue Forecast
| Revenue | 2024 | 2025 | 2026 | 2027 | 2028 | 2029 |
|---|---|---|---|---|---|---|
| High | n/a | 16.8M | 76.7M | |||
| Avg | n/a | 8.0M | 61.0M | |||
| Low | n/a | n/a | 48.2M |
Revenue Growth
| Revenue Growth | 2024 | 2025 | 2026 | 2027 | 2028 | 2029 |
|---|---|---|---|---|---|---|
| High | - | - | 856.1% | |||
| Avg | - | - | 660.6% | |||
| Low | - | - | 501.4% |
EPS Forecast
| EPS | 2024 | 2025 | 2026 | 2027 | 2028 | 2029 |
|---|---|---|---|---|---|---|
| High | -4.87 | -2.35 | -0.43 | |||
| Avg | -5.21 | -2.62 | -0.42 | |||
| Low | -5.47 | -2.84 | -0.40 |
EPS Growth
| EPS Growth | 2024 | 2025 | 2026 | 2027 | 2028 | 2029 |
|---|---|---|---|---|---|---|
| High | - | - | - | |||
| Avg | - | - | - | |||
| Low | - | - | - |
Sources: Price targets and analyst ratings provided by Benzinga. Revenue and EPS forecast data provided by Finnhub. The data is sourced from Wall Street analysts. Data disclaimer.